Omnicare — Q1 2011 Earnings Presentation
19 slides from Omnicare's earnings presentation, Apr 28, 2011
Slide 1: First Quarter 2011 Financial Results Supplemental Slides
Exhibit 99.2 First Quarter 2011 Financial Results Supplemental Slides
Slide 2: Forward-Looking Statements
Forward-Looking Statements Except for historical information discussed, the statements made today and listed within the following presentation slides are forward-looking statements that involve risks and uncertainties. Investors are cautioned that such statements are only predictions and that actual
Slide 3: Table of Contents
Table of Contents First Quarter 2011 Highlights…………………………………………..…….. 4 Operating Metrics - Script Data………………………………………………. 5 Operating Metrics - Bed Data………………………………………………… 6 Adjusted Gross Profit………………...…………………………………..…... 7 Adjusted Net Income………………………………………………..………… 8 Cash Flows……………………………………………
Slide 4: First Quarter 2011 Highlights
First Quarter 2011 Highlights • Scripts increased 1.5% over 1Q10; sequential scripts slightly lower due to fewer days in the period – Utilization increased sequentially while census was stable – Generic dispensing rate increased120 basis points sequentially • Qtr. ending number of beds served(1) up
Slide 5: Operating Metrics: Script Data
Operating Metrics Script Data • Scripts up 1.5% as compared with 1Q10 as the result of increased utilization • Sequentially, scripts were 0.3% lower due to fewer days in 1Q11 vs. 4Q10 • Census was relatively even with 4Q10 • Generic dispensing rate climbed 120 bps sequentially to 77.4% due largely t
Slide 6: Operating Metrics: Bed Data
Operating Metrics Bed Data • Organic additions increased compared to 4Q10. Overall additions lower sequentially due to decline in beds added by acquisitions on a sequential basis • 11.5% sequential improvement in bed losses, 50 bps sequential improvement in customer retention rate to 92.4% • Beds ad
Slide 7: Adjusted Gross Profit
Adjusted Gross Profit (1) (1) Each amount is reported independently. The sum of the individual amounts may not equal the sum of the separately presented amounts due to rounding. (2) Excludes special items. A reconciliation of non-GAAP information has been attached to our press release and is also av
Slide 8: Adjusted Net Income
Adjusted Net Income (1),(2) (1) All numbers shown exclude special items and discontinued operations. A reconciliation of non-GAAP information has been attached to our press release and is also available on our Web site under ‘Supplemental Financial Information’ from the ‘Investors’ page. (2) Each am
Slide 9: Cash Flows
Cash Flows(1) • Sequential increase in operating cash flow reflects decreases in working capital (primarily driven by a decrease in inventory levels and a decrease in DSOs of approximately 2 days) (1) Each amount is reported independently. The sum of individual amounts may not equal the sum of the s
Slide 10: Cash Deployment
Cash Deployment • Repurchased an additional 1.0 million shares ($28.7 million) during 1Q11 (in addition to 4.4 million shares repurchased in 2010) • $68.4 million of authorization remaining under current share repurchase program as of Mar. 31, 2011. • 1Q11 dividend of $0.0325 per share (1) During th
Slide 11: Capital Structure
Capital Structure Recent capital restructuring initiatives have extended maturities, providing more flexibility for capital allocation strategies (1) Assumes convertible debentures due 2035 are put to the company in 2015 with related tax recapture included and debt amounts shown are exclusive of una
Slide 12: 2011 Guidance
2011 Guidance Previous Guidance (1) Current Guidance (2) • Revenues $6.0B to $6.1B $6.0B to $6.1B • Adjusted Diluted EPS (3) $2.05 to $2.15 $2.05 to $2.15 • Cash Flow from Operations (3) $375M to $425M $375M to $425M Reaffirming full-year earnings per diluted share guidance(1) of $2.05 to $2.15(3) w
Slide 13: Longer-Term Targets
Longer-Term Targets (1) Target Double digit three-year CAGR • Adjusted Diluted EPS for the year ending 2013 • Cash Flow from Operations $450 million annually • Capital Returned to Shareholders Approximately 25% per year (2) Focus on continued debt reduction, • Capital Structure management of maturit
Slide 14: Appendix
Appendix 14
Slide 15: Working Capital Management
Working Capital Management Five Quarter Trend fe a 40 82 31.1 30.7 30 76 20 70 10 ~ 64 61.4 0 58 1010 2Q10 3Q10 4Q10 1Q11 a qeom Days of Inventory On Hand (DOH) eee Days Sales Outstanding (DSO) J
Slide 16: Selected Branded Drug Patent Expirations
Selected Branded Drug Patent Expirations (1),(2) 1Q 2011 2Q-4Q 2011 FY 2012 Lotrel Aromasin Actos Rythymol SR Concerta Diovan Vfend Fazaclo Geodon Tricor Femara Invega Xalatan Ferrlecit Lexapro Neurontin Gabitril Lidoderm Levaquin Plavix Lipitor Seroquel Nasacort AQ Singulair Primaxin Xopenex Uroxat
Slide 17: Regulatory Environment
Regulatory Environment Current Issues • Short-cycle dispensing – Final rule issued on April 4, 2011, requiring 14-day dispensing for branded drugs dispensed under Medicare Part D beginning January 1, 2013 – Pertains only to SNFs (assisted living and other chronic care facilities excluded) – Oral sol
Slide 18: First Quarter 2011 Financial Results Supplemental Slides
First Quarter 2011 Financial Results Supplemental Slides
Slide 19: Slide 19